Therative today announced it has received clearance from the Food & Drug Administration (FDA) to begin marketing ThermaClear, its innovative hand-held consumer medical device for the treatment of acne. The company also announced it has closed an additional round of expansion financing, bringing total capital raised to over $5 million. Therative will use the funds to help launch ThermaClear into the marketplace. Leading the round were Foundation Capital, RWI Ventures and Band of Angels.

"FDA clearance and the additional funding are two important milestones in our development," said Peter Scocimara, CEO of Therative. "Acne is a pervasive condition that has been without an effective solution. The FDA has cleared the way for us to bring our device to market and we intend to change the way people treat acne with our unique approach and ground-breaking technology."

"We are very pleased with the confidence our financial partners have expressed in ThermaClear and the Therative team," added Scocimara.

Foamix and Intendis Sign License Agreement for the Development of a Dermatological Foam

Intendis GmbH and Foamix Ltd., the leader in the development of topical foam delivery systems, announced today that they have executed a worldwide license agreement for a dermatological foam. The agreement was signed following successful completion of Foamix's development of a novel alcohol-free foam.

Under the terms of the agreement, Intendis is to pay Foamix a signing fee and milestone payments, as well as royalties based on net sales.

"We are pleased to announce this license agreement with Foamix. Foamix has a proven track record of developing innovative dermatological foams and we are confident that this product will be an important addition to our range of products", said Prof. Dr. Wolfgang Kehr, President and CEO of Intendis.

"This agreement with Intendis, a leader in the field of dermatology, validates our expertise in the development of dermatological foams", said Foamix CEO, Dr.